PMID- 36083133
OWN - NLM
STAT- MEDLINE
DCOM- 20230117
LR  - 20230222
IS  - 1552-4604 (Electronic)
IS  - 0091-2700 (Linking)
VI  - 63
IP  - 2
DP  - 2023 Feb
TI  - Thyroid Dysfunction in Non-Small Cell Lung Cancer With Immune Checkpoint 
      Inhibitors: A Meta-Analysis.
PG  - 210-218
LID - 10.1002/jcph.2150 [doi]
AB  - Immune checkpoint inhibitors (ICIs) have been established as the cornerstone for 
      advanced non-small cell lung cancer, while thyroid adverse events (AEs) 
      associated with ICIs have not been systematically documented. Therefore, we 
      performed a meta-analysis to evaluate the effect of ICI applications on the 
      thyroid of patients with non-small cell lung cancer. We performed a systematic 
      search of PubMed, the Cochrane Library, Web of Science, and Embase for eligible 
      randomized controlled trials up to December 2021. Clinical trials reporting 
      thyroid AEs including hypothyroidism, hyperthyroidism, and thyroiditis were 
      enrolled. The I(2)  statistic was also calculated to quantify the heterogeneity. 
      Data were evaluated as risk ratio (RR) and corresponding 95%CIs. A total of 10 
      randomized clinical trials involving 6154 patients were included in this 
      meta-analysis. ICI application was found to have a statistically significant 
      higher risk of all grade hypothyroidism (RR, 7.03; P < 0.0001), hyperthyroidism 
      (RR, 4.88; P < 0.0001), and thyroiditis (RR, 6.58; P = 0.0014) compared with the 
      chemotherapy group. Moreover, we demonstrated that second-line therapy 
      significantly increased the risk of all-grade hypothyroidism (RR, 7.03 [95%CI, 
      4.69-10.55]) and hyperthyroidism (RR, 4.88 [95%CI, 3.11-7.65]). Our meta-analysis 
      manifested that regimens with ICIs may significantly increase all grades of 
      hypothyroidism, hyperthyroidism, and thyroiditis. ICIs may induce the occurrence 
      and exacerbation of endocrine AEs compared with chemotherapy.
CI  - (c) 2022, The American College of Clinical Pharmacology.
FAU - Lin, Lanlan
AU  - Lin L
AD  - Department of Pulmonary and Critical Care Medicine, The Second Affiliated 
      Hospital of Fujian Medical University, Quanzhou, Fujian, People's Republic of 
      China.
FAU - Yang, Fan
AU  - Yang F
AD  - Department of Respiratory Medicine, Fujian Medical University Union Hospital, 
      Fuzhou, Fujian, People's Republic of China.
FAU - Lin, Guofu
AU  - Lin G
AD  - Department of Pulmonary and Critical Care Medicine, The Second Affiliated 
      Hospital of Fujian Medical University, Quanzhou, Fujian, People's Republic of 
      China.
FAU - Chen, Xiangqi
AU  - Chen X
AD  - Department of Respiratory Medicine, Fujian Medical University Union Hospital, 
      Fuzhou, Fujian, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20221102
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Immune Checkpoint Inhibitors/adverse effects
MH  - *Lung Neoplasms/drug therapy
MH  - *Thyroid Diseases/chemically induced
MH  - *Hypothyroidism/chemically induced/drug therapy
MH  - *Hyperthyroidism/chemically induced/drug therapy
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - CTLA-4 inhibitors
OT  - PD-1/PD-L1 inhibitors
OT  - non-small cell lung cancer
OT  - thyroid adverse events
EDAT- 2022/09/10 06:00
MHDA- 2023/01/18 06:00
CRDT- 2022/09/09 09:43
PHST- 2022/06/12 00:00 [received]
PHST- 2022/08/29 00:00 [accepted]
PHST- 2022/09/10 06:00 [pubmed]
PHST- 2023/01/18 06:00 [medline]
PHST- 2022/09/09 09:43 [entrez]
AID - 10.1002/jcph.2150 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2023 Feb;63(2):210-218. doi: 10.1002/jcph.2150. Epub 2022 Nov 
      2.